PerkinElmer, Inc. has entered into an agreement to acquire Sirion Biotech GmbH, a, global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.   Headquartered in Munich, Germany, privately held Sirion has approximately 50 employees based in Germany, the U.S. and France. The company has established a strong licensing portfolio leveraged by over a dozen major pharmace...